Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Succession doubts cloud Apotex future after billionaire owner's death

Published 2017-12-21, 05:19 p/m
© Reuters.  Succession doubts cloud Apotex future after billionaire owner's death
AGN
-
TEVA
-

* Sherman had no succession plan in place before death -sources

* Billionaire's children not involved in business

* Death could leave business vulnerable to takeover approach

* Apotex involved in ongoing litigation with Teva

By Matt Scuffham

TORONTO, Dec 21 (Reuters) - Canadian pharmaceuticals billionaire Barry Sherman failed to implement a succession plan at his Apotex business before his death last week, two business associates told Reuters, potentially leaving it vulnerable to takeover approaches.

The bodies of Sherman, 75, and his wife Honey, 70, were found in their Toronto mansion last week and their deaths are under investigation by Toronto's homicide squad. A memorial service was held on Thursday. had always resisted approaches from trade buyers and never wanted to take the generic drugmaker public, the associates said, preferring to keep control and not involve outside shareholders.

Despite stepping down as chief executive in 2012, the self-confessed workaholic continued to work seven-day weeks and twelve-hour days. None of Sherman's four children were interested in running the business and only one had worked at the company, the associates said.

Sherman's son Jonathan, who has a degree in industrial engineering from Columbia University, took at job at the firm after graduating but quit after less than a year.

Sherman founded Apotex in 1974 and grew it through a strategy of launching hundreds of lawsuits against competitors to overturn patent protection for their drugs. Apotex would then manufacture cheaper identical products that did not carry a brand name.

The company now employs more than 10,000 worldwide with annual sales exceeding C$2 billion ($1.6 billion).

The associates said no formal sales process is underway. Any approach would come as the world's biggest generic drug companies are grappling with declining drug prices and intensifying competition.

Any potential buyer would also require an appetite for litigation, the associates said, since Apotex is regularly involved in legal actions over patents.

And Teva Pharmaceuticals Industries TEVA.TA TEVA.N , the world's biggest maker of generic drugs, is currently in a legal dispute with Apotex over allegations a former Teva executive shared trade secrets with Apotex CEO Jeremy Desai.

Teva is also weighed by $35 billion in debt it took on to acquire Allergan's AGN.N Actavis (NYSE:AGN) generic drug business for $40.5 billion last year. Last week it said it would axe 14,000 jobs. Teva spokeswoman in Israel had no immediate comment when asked about any takeover plans or the status of its legal case against Apotex.

($1 = 1.2728 Canadian dollars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.